Member Info for chester18

We are at the cusp of a redefining of Scancell Holdings. There is a very real chance that enough finance has been pledged that we do indeed have the opportunity to ‘go it alone’.

That will take an enormous amount of confidence in the eventual success of the phase 3 trial, the rewards however would be enormous if ‘Standard of Care’ is the outcome.

One issue with going it alone is the amount of finance that would be needed to both run the reg trial and develop Modi, Sc134 and GlyMabs.

Our board has a job on its hands to negotiate the correct ‘shareholder value’ for any deals. What to hold on to, what to sell or partner and how long each potential route will take to create that value.

Tough times for Phil and his team 🤔

Nice spot dragon101 …. 👍

We don’t know who is attending for Scancell but it’s good to know one of the team are there to spread the message.

ISCIB1+ Phase 3 Trial :

“Planning is advancing at pace”.

I like the sound of that 👊👊

Hi Ray

I suppose that’s my point, Scancell and the technique use to engage the immune system is still very much under the radar.

These kinds of announcements 77% v 43% and FDA Fast Track are bringing Scancell into the mainstream consciousness. It’s been a slow trickle so far but I think we are close to it becoming a torrent.

🤞🤞🤞

Hi Marcus

Listening to those two enthuse about the 77% PFS verses 43% was really good to hear. To show just how clever Scancell’s technology is they found it difficult to explain how iSCIB1+ works.

Vaccine is probably not the best description of Immunobody but does Therapy fall short ?

Anyway it’s important to note that Scancell’s approach is unique and may well become the dominate way to enhance Checkpoint Inhibitors in the cancer setting.

After all this time the cancer / oncology community is beginning to acknowledge just how impactful Immunobody and soon ModiTope is, when added to Checkpoints in the treatment of late stage cancers.

Hi C11

Thank you.

That article is predominantly talking about initial trial approval times. My puzzlement is why the delay when a company are in a Phase 2 trial and the data is mounting up to provide evidence towards a Phase 3.

There must be a technical hitch that is important enough for MHRA to seek more evidence where it seems perfectly ok for the FDA to give their blessing.

Could it just be something to do with the clinical procedures inside the NHS ?

What ever it is the clinical team at Scancell must be working double time to ensure the delay doesn’t push into H2.

Being positive I’m going to say approval definitely before Friday May 29th 👊👊

So it looks very likely that April is going to close and still no word with regards to the UK and European Phase 3 Applications.

There is obviously some technical reason why the Phase 3 has not automatically passed their assessment but the reason for such a delay is not easy to fathom.

Is there anyone reading this chat board who has more of an understanding as to what could possibly be so technically challenging, that is also above and beyond the current running of the phase 2 trail to MRHA standards ?

Any input would be greatly appreciated.

I think as this vital piece of news sinks in the SP will rise. Not by a great amount but anywhere near 14.5p would be a start.

We are still awaiting MHRA and EMA approvals and they cannot be too far away.

Not forgetting that a full Modi1 update has been promised H1 2026 and the Renal Cell Carcinoma results could be extremely positive.

This is an extremely important designation and definitely strengthens any ongoing negotiations .

Another positive step forward 👊

Only that it is unusual for a well regarded director to go at such pace when there are no clear circumstances that warrant it.

Sath was doing a very credible job and seemed to be well liked and respected. So why the hurry ?

That VanVan is the question and it allows for a very strategic list of why’s ……

Is the new CFO more capable in the context of listing on the Nasdaq ?

Is Sath moving to GlyMab Theraputics early in May ?

We like to fill the void with interpretations and just may be, we could be right that it means ‘the changes are about to happen’.

Well I’m sure we all hope so !

It does feel like we are very close to finding out exactly how things are going to proceed.

The fact that Sath left so quickly ( 24th April ) when normally there would be a 3 month period. It suggests to me that there is a good possibility that the beginning of May will yield some important results. Either Data, Approvals, GlyMab Theraputics or Nasdaq confirmation.

I’m quite content if Scancell decide to go it alone as the market, especially if we are on the Nasdaq, will value the size of the potential prize.

But I can’t see BMS, Merck or BionTech letting a minnow become a monster.

As frustrating this no news period is we must remind ourselves that the clinical trials are still ongoing and gathering data.

I was being practical and a touch pessimistic when I said that the MHRA approval could be end April. Now we have reached the last day of the AACR conference and rapidly approaching the last week of April, I’m beginning to wonder why there hasn’t been that MHRA approval RNS.

The FDA was very straightforward and I thought that would be the more exacting set of rules to negotiate. Obviously I was wrong in my assessment.

Given that we are currently running the SCOPE trial phase 2 under MHRA guidance what could be different or difficult about running the Phase 3 ?

Anyone any ideas ?

Eric Rubin is an interesting pick for our Advisory Board. Incredible if there is genuine interest from Natera and by association also by Merck.

I’m still convinced that BMS can’t let iSCIB1+ slip from their grasp as they stand to lose control of the SOC in Unresectable Advanced Melanoma.

Q : If another company partners Scancell through to Approval how easy or difficult would it be to swap to Generic Checkpoints and cut out BMS altogether ?

Taken from a post by Cleanerworld on 25th March. As published on LinkedIn by Scancell.

‘Scancell will be at the AACR Annual Meeting 2026 in San Diego, from April 17-22, and will have a poster presentation.

Title: SCOPE, A phase 2 clinical trial with off-the-shelf DNA plasmid vaccine in first line advanced melanoma combined with check point blockade, shows good T cell responses which correlate with long progression free survival

Session Title: Phase II Clinical Trials, April 21 from 2-5pm ET

Location: Poster Section 50, Poster Board Number 2’

Soo we know that Scancell will have a presence but not to what level other than this poster.

Yesterday was obviously down to small select group of high powered traders with their fingers on the pulse.

On the train yesterday morning arriving early into the financial district there was a suited guy speaking loudly on the phone to his inner city ‘Skip Hire Empire’ mate about the recent AI data crunching.

“Yeah Mate, keep this under your hat for now but the New Skip1 data is fantastic compared with the SOC ( Static Overload Capacity ) and the PFS ( Physical Forward Shipment ) is going to blow the market away. So I’m definitely going to order that Aston Martin”.

Never mind ‘non fake’ news will arrive soon 👍👍

What are these people doing. Do they not know how rude it is to buy shares at such inflated prices when there hasn’t been an RNS. How can they assess the future with such certainty…. ?

Not only that they’re spending 10’s of 1,000’s without flinching.

The world’s gone mad …………

Do they know something we don’t 🤔😉🤫

Thanks Balerno2

That’s a very important fact that I certainly wasn’t aware of. I would have thought that the Scancell senior management team would be aware of that requirement.

If that is part of the hold up it’s an interesting challenge as what comes first the cart or the horse ??

This weekend is the 2026 meeting of AACR and we know Scancell will be attending. It’s the largest event of its kind and definitely the place to talk to large Pharma senior management. Also a great platform ‘if’ there is any significant news to release.

In all my guess work I anticipated the approvals from MHRA and EMA to land Mid to Late April. If those approvals do not land inside the next 4 weeks then some element of our proposed Ph3 trial has not been accepted by MHRA. So on the balance of probability I’m sticking with ‘by the end of April’.

FDA ‘Breakthrough Therapy Designation’ must also be in the final stages. Maybe there have been a few back and forth issues to be overcome but we can assume the request process and evaluation is well on its way.

Lastly, GenMab will likely announce that they have approval to start a trial or trials using out GlyMab target, at some point in the next ??? 🙄. At which point we will receive between £3m to £6m to boost the coffers.

So good luck all you stalwart Scancell faithful 🤞🤞🤞🤞🤞 ( including me obviously ).

That’s a healthy buy at the full ask and probably explains why the SP movement has been steadily heading in a more positive direction.

Could be an isolated trade but any upward rises have to start somewhere and why not from a committed 231,000 buy. 🤞

Looks like Replimune have a tie up with BMS which helps. They also have a large fully owned manufacturing facility.

That’s what comes of being valued in the US rather than the UK’s AIM market.

The day it’s announced that Scancell has achieved a partnership with a large pharma the MCap will exceed £300m.

The next 6 to 8 weeks have the potential to radically change the market sentiment around Scancell and their immune system technology.

GLA 👊